Heather Manna, VP, Global Regulatory Affairs, Inceptua Early Access, answers questions about Real World Data and Early Access.
Elevar Therapeutics Inc. Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe
December 28 2020, Elevar Therapeutics, Inc, a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that it has entered into an exclusive agreement with Inceptua Group for the distribution and commercialization of Apealea® (paclitaxel micellar) in Europe.
Under the terms of the agreement, Inceptua will have exclusive rights to distribute and commercialize Apealea in Europe. These rights do not extend to the Nordic countries (Denmark, Finland, Norway, Sweden, Iceland).
Apealea® (paclitaxel micellar) is a non-Cremophor based formulation of paclitaxel. It received marketing authorization from the European Commission in 2018, which was the first approval in Europe for a non-Cremophor EL paclitaxel in ovarian cancer and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA).
To access the full press release, please follow the link below where you will be taken directly to the Elevar Therapeutics Inc, website. Inceptua accepts no responsibility for the content or services of the linked site:
Latest News and Insights
We asked Mark Bainbridge, Sr. Director, Inceptua Early Access, to answer 5 quick questions about the important role Early Access is playing…